Eli Lilly (LLY) Q3 2026 Earnings Call Transcript

Eli Lilly reported Q3 2026 revenue of $24.4 billion, up 39% year over year, and raised FY 2026 revenue guidance to $91 billion–$92 billion on strong incretin demand. Mounjaro revenue rose 65% to $10.7 billion and Zepbound increased 48% to $5.3 billion; non-GAAP EPS was $7.48, including $4.57 per share of acquired IPR&D charges. U.S. realized pricing remained a headwind, down 10% excluding a favorable rebate-and-discount estimate adjustment, while management expects 2027 revenue to lack about $2 billion of one-time 2026 benefits. Lilly also reported positive pipeline trial results, announced $11.5 billion in new U.S. manufacturing facilities, and returned $1.5 billion in dividends and $400 million through repurchases during the quarter.

Analysis

The key investment question is whether Lilly can sustain volume growth as net pricing falls—not whether demand is currently strong. Broader access can expand the treated population, but Medicare/Medicaid growth and self-pay mix may lower revenue per prescription; rising prescription counts therefore need to translate into durable net sales and persistence. A deceleration in reported growth could coexist with healthy patient additions, making channel mix and net price more informative than headline prescriptions.

Near term, the raised outlook and operating leverage support the bull case, but the earnings quality is less clean than the headline suggests: 2026 benefited from roughly $2 billion of items not expected to recur in 2027, including rebate-estimate and milestone effects. That creates a comp headwind just as pricing pressure persists. The next 1–3 month catalyst is the December 7 pipeline update; retatrutide and combination data may extend the growth narrative, but clinical results are not revenue, and tolerability and Phase 3 replication remain material gates.

Over 6–18 months, manufacturing expansion reduces supply constraints if demand persists, but also raises the cost of a demand or access reversal. Medicare program continuity and payer coverage are pivotal policy catalysts. Novo Nordisk is the clearest competitive counterparty: Lilly’s share gains pressure its growth expectations, while price competition could benefit patients but compress category economics. The contrarian risk is that investors extrapolate prescription growth while underweighting lower realized prices and the 2027 one-off comparison. The thesis weakens if volume growth slows materially, net pricing deteriorates faster than volume offsets it, or access expansion fails to persist.

Key Decisions for Investors

• Do not chase the earnings reaction. Maintain or initiate a measured long LLY position on post-event weakness, contingent on prescription growth remaining strong and reported net-price pressure staying consistent with management’s volume-offset outlook.
• Use the December 7 investor event as a catalyst checkpoint, not a reason to pre-pay for pipeline upside. Upgrade conviction only if management clarifies Phase 3 timing, tolerability, and commercial differentiation for next-generation obesity assets.
• Track 2027 guidance for the bridge between underlying demand and the roughly $2 billion nonrecurring 2026 benefit. Falsify the bullish thesis if volume growth no longer offsets price/mix pressure or guidance implies meaningful deterioration in underlying demand.
• Treat ATAI as an event-driven watch item only: verify the completed acquisition’s consideration, remaining public-float status, and any residual transaction mechanics before taking a position; the call alone does not establish standalone upside.